Skip to main content
Erschienen in: International Journal of Colorectal Disease 3/2020

01.03.2020 | Original Article

Clinical assessment of risk factors for infection in inflammatory bowel disease patients

verfasst von: Joan Tosca, Natalia Garcia, Isabel Pascual, Marta Maia Bosca-Watts, Rosario Anton, Ana Sanahuja, Pilar Mas, Francisco Mora, Miguel Minguez

Erschienen in: International Journal of Colorectal Disease | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recognizing patients with inflammatory bowel disease who are prone to infection would enable the adjustment of the type and intensity of immunosuppressive treatment. The aim of this study was to identify a clinical profile of risk for infections in IBD patients, based on the interaction of immunosuppressive treatment with factors inherent to the patient.

Methods

A case-control study was performed among patients older than 18 years. Patients with any significant infection (any kind of severe or recurrent infection according to standard clinical criteria or a critical enough infection according to the patient) were defined as cases. Both cases and controls were randomly selected in a 1:3 ratio. All the period from diagnosis to the end of recruitment (June 2016) was analyzed. Risk factors for infection were identified by logistic regression analysis; the strength of association was reported by odds ratio (OR) with 95% confidence interval (95%CI).

Results

A total of 112 cases and 270 controls were included. The independent risk factors for significant infection are the number of immunosuppressants (one drug: OR 1.28, 95% CI 0.53–3.11, two drugs: OR 2.37, 95% CI 1.01–5,56, and three drugs: OR 5.84, 95% CI 1.57–21.72), body mass index (OR 1.08; 95 %CI 1,01–1,16), the degree of comorbidity (OR 1.52; 95% CI 1.04–2.21), and the intensity of inflammatory activity (OR 1.43; 95% CI 1.19–1.71).

Conclusions

Regardless of immunosuppression, several patient factors such as comorbidity, body mass index, or the inflammatory activity of the disease determine the individual risk of infectious complications and should be considered for an adequate risk assessment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF, European Crohn's and Colitis Organisation (ECCO) (2014) European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8:443–468CrossRef Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF, European Crohn's and Colitis Organisation (ECCO) (2014) European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8:443–468CrossRef
2.
Zurück zum Zitat Toruner M, Loftus EV Jr, Harmsen WS et al (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134:929–936CrossRef Toruner M, Loftus EV Jr, Harmsen WS et al (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134:929–936CrossRef
3.
Zurück zum Zitat Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11(6):954–963CrossRef Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11(6):954–963CrossRef
4.
Zurück zum Zitat Lichtenstein GR, Feagan BG, Cohen RD et al (2006) Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 4:621–630 Erratum in: Clin Gastroenterol Hepatol 2006;4:931CrossRef Lichtenstein GR, Feagan BG, Cohen RD et al (2006) Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 4:621–630 Erratum in: Clin Gastroenterol Hepatol 2006;4:931CrossRef
5.
Zurück zum Zitat Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF (2008) Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6:644–653CrossRef Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF (2008) Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6:644–653CrossRef
6.
Zurück zum Zitat Lichtenstein GR, Cohen RD, Feagan BG et al (2008) Safety of infliximab and other Crohn’s disease therapies; TREAT™ registry data with 24,575 patient-years of follow-up. Am J Gatroenterol 103:S–436 Lichtenstein GR, Cohen RD, Feagan BG et al (2008) Safety of infliximab and other Crohn’s disease therapies; TREAT™ registry data with 24,575 patient-years of follow-up. Am J Gatroenterol 103:S–436
7.
Zurück zum Zitat Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ (2012) Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 107:1409–1422CrossRef Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ (2012) Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 107:1409–1422CrossRef
8.
Zurück zum Zitat Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, van Assche G, Vermeire S, Rutgeerts P (2009) Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58:501–508CrossRef Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, van Assche G, Vermeire S, Rutgeerts P (2009) Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58:501–508CrossRef
9.
Zurück zum Zitat Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M (2013) A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammmatory bowel disease. J Gastroenterol 48:595–600CrossRef Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M (2013) A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammmatory bowel disease. J Gastroenterol 48:595–600CrossRef
10.
Zurück zum Zitat Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD (2016) Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol 111:1806–1815CrossRef Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD (2016) Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol 111:1806–1815CrossRef
11.
Zurück zum Zitat Nyboe Andersen N, Pasternak B, Friis-Moller N et al (2015) Association between tumour necrosis factor- inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 350:h2809CrossRef Nyboe Andersen N, Pasternak B, Friis-Moller N et al (2015) Association between tumour necrosis factor- inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 350:h2809CrossRef
12.
Zurück zum Zitat Kirchgesner J, Lemaitre M, Carrat F et al (2018) Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 155:337–346CrossRef Kirchgesner J, Lemaitre M, Carrat F et al (2018) Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 155:337–346CrossRef
13.
Zurück zum Zitat Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F, European Crohn’s and Colitis Organisation [ECCO] (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohns Colitis 11:649–670CrossRef Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F, European Crohn’s and Colitis Organisation [ECCO] (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohns Colitis 11:649–670CrossRef
14.
Zurück zum Zitat Gomollón F, Dignass A, Annese V, Tilg H, van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P, ECCO (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11:3–25CrossRef Gomollón F, Dignass A, Annese V, Tilg H, van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P, ECCO (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11:3–25CrossRef
15.
Zurück zum Zitat WHO (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization WHO (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization
16.
Zurück zum Zitat (1993) Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep 42:1–18 (1993) Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep 42:1–18
17.
Zurück zum Zitat Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294–2300CrossRef Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294–2300CrossRef
18.
Zurück zum Zitat Ananthakrishnan AN, McGinley EL (2013) Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 7:107–112CrossRef Ananthakrishnan AN, McGinley EL (2013) Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 7:107–112CrossRef
19.
Zurück zum Zitat Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF (2008) Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 57:549–558CrossRef Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF (2008) Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 57:549–558CrossRef
20.
Zurück zum Zitat Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A (2011) Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 9:30–35CrossRef Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A (2011) Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 9:30–35CrossRef
21.
Zurück zum Zitat Gavazzi G, Krause KH (2002) Ageing and infection. Lancet Infect Dis 2:659–666CrossRef Gavazzi G, Krause KH (2002) Ageing and infection. Lancet Infect Dis 2:659–666CrossRef
22.
Zurück zum Zitat Lord JM, Butcher S, Killampali V, Lascelles D, Salmon M (2001) Neutrophil ageing and immunesenescence. Mech Ageing Dev 122:1521–1535CrossRef Lord JM, Butcher S, Killampali V, Lascelles D, Salmon M (2001) Neutrophil ageing and immunesenescence. Mech Ageing Dev 122:1521–1535CrossRef
23.
Zurück zum Zitat Castle SC (2000) Clinical relevance of age-related immune dysfunction. Clin Infect Dis 31:578–585CrossRef Castle SC (2000) Clinical relevance of age-related immune dysfunction. Clin Infect Dis 31:578–585CrossRef
24.
Zurück zum Zitat Borren NZ, Ananthakrishnan AN (2019) Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 17:1736–1743CrossRef Borren NZ, Ananthakrishnan AN (2019) Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 17:1736–1743CrossRef
25.
Zurück zum Zitat Gershwin ME, Borchers AT, Keen CL (2000) Phenotypic and functional considerations in the evaluation of immunity in nutritionally compromised hosts. J Infect Dis 182(Suppl 1):S108–S114CrossRef Gershwin ME, Borchers AT, Keen CL (2000) Phenotypic and functional considerations in the evaluation of immunity in nutritionally compromised hosts. J Infect Dis 182(Suppl 1):S108–S114CrossRef
26.
Zurück zum Zitat Büning C, von Kraft C, Hermsdorf M, Gentz E, Wirth EK, Valentini L, Haas V (2015) Visceral adipose tissue in patients with Crohn’s disease correlates with disease activity, inflammatory markers, and outcome. Inflamm Bowel Dis 21:2590–2597CrossRef Büning C, von Kraft C, Hermsdorf M, Gentz E, Wirth EK, Valentini L, Haas V (2015) Visceral adipose tissue in patients with Crohn’s disease correlates with disease activity, inflammatory markers, and outcome. Inflamm Bowel Dis 21:2590–2597CrossRef
27.
Zurück zum Zitat Karmiris K, Koutroubakis IE, Xidakis C et al (2006) Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2:100–105CrossRef Karmiris K, Koutroubakis IE, Xidakis C et al (2006) Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2:100–105CrossRef
28.
Zurück zum Zitat Waluga M, Hartleb M, Boryczka G et al (2014) Serum adipokines in inflammatory bowel disease. World J Gastroenterol 14:6912–6917CrossRef Waluga M, Hartleb M, Boryczka G et al (2014) Serum adipokines in inflammatory bowel disease. World J Gastroenterol 14:6912–6917CrossRef
29.
Zurück zum Zitat Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, Sulz MC, Fried M, Rogler G, Scharl M (2016) The impact of azathioprine-associated lymphopenia on the onset of opportunistic infections in patients with inflammatory bowel disease. PLoS One 11(5):e0155218CrossRef Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, Sulz MC, Fried M, Rogler G, Scharl M (2016) The impact of azathioprine-associated lymphopenia on the onset of opportunistic infections in patients with inflammatory bowel disease. PLoS One 11(5):e0155218CrossRef
30.
Zurück zum Zitat Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent. N Engl J Med 345(15):1098–1104CrossRef Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent. N Engl J Med 345(15):1098–1104CrossRef
31.
Zurück zum Zitat Nuño JLC, Mendoza MIV, Domènech E, de Acosta MB, Comas ME, Gisbert JP et al (2013) Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral? en la enfermedad inflamatoria intestinal (2013). Gastroenterol Hepatol 36(3):127–146CrossRef Nuño JLC, Mendoza MIV, Domènech E, de Acosta MB, Comas ME, Gisbert JP et al (2013) Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral? en la enfermedad inflamatoria intestinal (2013). Gastroenterol Hepatol 36(3):127–146CrossRef
32.
Zurück zum Zitat Zabana Y, Rodríguez L, Lobatón T, Gordillo J, Montserrat A, Mena R et al (2019) Relevant infections in inflammatory bowel disease, and their relationship with immunosuppressive therapy and their effects on disease mortality. J Crohns Colitis Zabana Y, Rodríguez L, Lobatón T, Gordillo J, Montserrat A, Mena R et al (2019) Relevant infections in inflammatory bowel disease, and their relationship with immunosuppressive therapy and their effects on disease mortality. J Crohns Colitis
33.
Zurück zum Zitat Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V (2014) Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 46(7):547–554CrossRef Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V (2014) Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 46(7):547–554CrossRef
34.
Zurück zum Zitat Brassard P, Bitton A, Suissa A, Sinyavskaya L, Patenaude V, Suissa S (2014) Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol 109(11):1795–1802 quiz 1803CrossRef Brassard P, Bitton A, Suissa A, Sinyavskaya L, Patenaude V, Suissa S (2014) Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol 109(11):1795–1802 quiz 1803CrossRef
35.
Zurück zum Zitat Baumgart D (2011) Crohn’s disease and ulcerative colitis. Springer Baumgart D (2011) Crohn’s disease and ulcerative colitis. Springer
Metadaten
Titel
Clinical assessment of risk factors for infection in inflammatory bowel disease patients
verfasst von
Joan Tosca
Natalia Garcia
Isabel Pascual
Marta Maia Bosca-Watts
Rosario Anton
Ana Sanahuja
Pilar Mas
Francisco Mora
Miguel Minguez
Publikationsdatum
01.03.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 3/2020
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-019-03501-0

Weitere Artikel der Ausgabe 3/2020

International Journal of Colorectal Disease 3/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.